Nasdaq

Biohaven Stock Moving on Migraine Med Results

Biohaven Pharmaceutical Holding Co. (BHVN) share price surged 13.6% to close at $112.25 on July 7. Biohaven Pharmaceutical is a commercial-stage biotechnology company. Its primary focus is on the ...
FiercePharma

After Biohaven stopped teasing Nurtec's quarterly performance, should investors be worried?

Biohaven Pharmaceuticals has been offering early looks at the performance of its closely watched migraine drug launch since the fourth quarter of 2020. So, when the company recently stopped the ...
Nasdaq

Biohaven's (BHVN) Nurtec Gets FDA Nod for Migraine Prevention

Biohaven Pharmaceutical Holding Company Ltd. BHVN announced that the FDA has approved its oral CGRP antagonist Nurtec ODT (rimegepant) for the preventive treatment of migraine. Notably, Nurtec ODT was ...
WTEN

BIOHAVEN ANNOUNCES PRELIMINARY 4Q2021 AND FULL YEAR NET PRODUCT REVENUE FOR NURTEC ODT, MARKET LEADING NOVEL MIGRAINE THERAPY

NEW HAVEN, Conn., Jan. 6, 2022 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates, ...
WOOD-TV

Biohaven Announces Expanded Patient Access to Nurtec® ODT (rimegepant), Achieving Best-in-Class Commercial Insurance Coverage and Label Update

- Insurance Coverage of Nurtec ODT Now Totals 96 Percent of Commercial Lives or Approximately 255 Million Lives Covered in All Channels - Nurtec ODT Label Expanded to include Lactation Data in the ...